Ask AI
ProCE Banner Activity

Interactive Tool for the Treatment of R/R CLL: An International Expert Perspective

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with R/R CLL with 5 renowned international experts.

Released: June 11, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Lymphoma Coalition.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Partners

Lymphoma Coalition

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of global hematologists, oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals caring for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences to optimize clinical outcomes for patients with relapsed/refractory CLL/SLL, considering available evidence, local expert recommendations, regional guidelines, and disease/patient factors

  • Appraise emerging clinical evidence for novel BTK-targeted therapies and the clinical implications for management of relapsed/refractory CLL/SLL

  • Assess resistance mutations in patients with relapsed/refractory CLL/SLL who progressed on or following covalent BTK inhibitor therapy

  • Implement multidisciplinary team processes to mitigate the risk of treatment- and disease-related complications in patients with relapsed/refractory CLL/SLL

  • Apply shared decision-making strategies to support patient quality of life and engagement in care for relapsed/refractory CLL/SLL

Financial Disclosures

Primary Author

Matthew S. Davids, MD, MMSc: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, Schrödinger; researcher: Ascentage, AstraZeneca, MEI Pharma.

Stéphane Lepretre, MD, has no relevant financial relationships to disclose.

Javier Loscertales, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.